Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366339435> ?p ?o ?g. }
- W4366339435 endingPage "3492" @default.
- W4366339435 startingPage "3486" @default.
- W4366339435 abstract "Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432) showed that avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free after 1L platinum-containing chemotherapy. Avelumab 1L maintenance treatment is now a standard of care for aUC. Here, we report updated data with ≥ 2 years of follow-up in all patients, including OS (primary end point), PFS, safety, and additional novel analyses. Patients were randomly assigned 1:1 to receive avelumab plus BSC (n = 350) or BSC alone (n = 350). At data cutoff (June 4, 2021), median follow-up was 38.0 months and 39.6 months, respectively; 67 patients (19.5%) had received ≥2 years of avelumab treatment. OS remained longer with avelumab plus BSC versus BSC alone in all patients (hazard ratio, 0.76 [95% CI, 0.63 to 0.91]; 2-sided P = .0036). Investigator-assessed PFS analyses also favored avelumab. Longer-term safety was consistent with previous analyses; no new safety signals were identified with longer treatment duration. In conclusion, longer-term follow-up continues to show clinically meaningful efficacy benefits with avelumab 1L maintenance plus BSC versus BSC alone in patients with aUC. An interactive visualization of data reported in this article is available." @default.
- W4366339435 created "2023-04-20" @default.
- W4366339435 creator A5002541288 @default.
- W4366339435 creator A5004985848 @default.
- W4366339435 creator A5016654748 @default.
- W4366339435 creator A5026717218 @default.
- W4366339435 creator A5027991868 @default.
- W4366339435 creator A5036848171 @default.
- W4366339435 creator A5037677450 @default.
- W4366339435 creator A5041526616 @default.
- W4366339435 creator A5046444872 @default.
- W4366339435 creator A5048855238 @default.
- W4366339435 creator A5057146015 @default.
- W4366339435 creator A5064767706 @default.
- W4366339435 creator A5074756323 @default.
- W4366339435 creator A5086078883 @default.
- W4366339435 creator A5088582666 @default.
- W4366339435 creator A5089861374 @default.
- W4366339435 date "2023-07-01" @default.
- W4366339435 modified "2023-10-17" @default.
- W4366339435 title "Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up" @default.
- W4366339435 cites W1996573170 @default.
- W4366339435 cites W2004065537 @default.
- W4366339435 cites W2102297555 @default.
- W4366339435 cites W2541420108 @default.
- W4366339435 cites W2800435899 @default.
- W4366339435 cites W2800509387 @default.
- W4366339435 cites W2927051995 @default.
- W4366339435 cites W3007123110 @default.
- W4366339435 cites W3015816649 @default.
- W4366339435 cites W3024551702 @default.
- W4366339435 cites W3087464965 @default.
- W4366339435 cites W3087466624 @default.
- W4366339435 cites W3112964456 @default.
- W4366339435 cites W3164197656 @default.
- W4366339435 cites W3209393335 @default.
- W4366339435 cites W4200026971 @default.
- W4366339435 cites W4213300100 @default.
- W4366339435 cites W4281848279 @default.
- W4366339435 doi "https://doi.org/10.1200/jco.22.01792" @default.
- W4366339435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37071838" @default.
- W4366339435 hasPublicationYear "2023" @default.
- W4366339435 type Work @default.
- W4366339435 citedByCount "11" @default.
- W4366339435 countsByYear W43663394352023 @default.
- W4366339435 crossrefType "journal-article" @default.
- W4366339435 hasAuthorship W4366339435A5002541288 @default.
- W4366339435 hasAuthorship W4366339435A5004985848 @default.
- W4366339435 hasAuthorship W4366339435A5016654748 @default.
- W4366339435 hasAuthorship W4366339435A5026717218 @default.
- W4366339435 hasAuthorship W4366339435A5027991868 @default.
- W4366339435 hasAuthorship W4366339435A5036848171 @default.
- W4366339435 hasAuthorship W4366339435A5037677450 @default.
- W4366339435 hasAuthorship W4366339435A5041526616 @default.
- W4366339435 hasAuthorship W4366339435A5046444872 @default.
- W4366339435 hasAuthorship W4366339435A5048855238 @default.
- W4366339435 hasAuthorship W4366339435A5057146015 @default.
- W4366339435 hasAuthorship W4366339435A5064767706 @default.
- W4366339435 hasAuthorship W4366339435A5074756323 @default.
- W4366339435 hasAuthorship W4366339435A5086078883 @default.
- W4366339435 hasAuthorship W4366339435A5088582666 @default.
- W4366339435 hasAuthorship W4366339435A5089861374 @default.
- W4366339435 hasBestOaLocation W43663394351 @default.
- W4366339435 hasConcept C121608353 @default.
- W4366339435 hasConcept C126322002 @default.
- W4366339435 hasConcept C143998085 @default.
- W4366339435 hasConcept C203092338 @default.
- W4366339435 hasConcept C207103383 @default.
- W4366339435 hasConcept C2776694085 @default.
- W4366339435 hasConcept C2777381376 @default.
- W4366339435 hasConcept C2777701055 @default.
- W4366339435 hasConcept C2780030458 @default.
- W4366339435 hasConcept C2780352672 @default.
- W4366339435 hasConcept C2780739268 @default.
- W4366339435 hasConcept C2911057145 @default.
- W4366339435 hasConcept C3019882237 @default.
- W4366339435 hasConcept C44249647 @default.
- W4366339435 hasConcept C535046627 @default.
- W4366339435 hasConcept C71924100 @default.
- W4366339435 hasConceptScore W4366339435C121608353 @default.
- W4366339435 hasConceptScore W4366339435C126322002 @default.
- W4366339435 hasConceptScore W4366339435C143998085 @default.
- W4366339435 hasConceptScore W4366339435C203092338 @default.
- W4366339435 hasConceptScore W4366339435C207103383 @default.
- W4366339435 hasConceptScore W4366339435C2776694085 @default.
- W4366339435 hasConceptScore W4366339435C2777381376 @default.
- W4366339435 hasConceptScore W4366339435C2777701055 @default.
- W4366339435 hasConceptScore W4366339435C2780030458 @default.
- W4366339435 hasConceptScore W4366339435C2780352672 @default.
- W4366339435 hasConceptScore W4366339435C2780739268 @default.
- W4366339435 hasConceptScore W4366339435C2911057145 @default.
- W4366339435 hasConceptScore W4366339435C3019882237 @default.
- W4366339435 hasConceptScore W4366339435C44249647 @default.
- W4366339435 hasConceptScore W4366339435C535046627 @default.
- W4366339435 hasConceptScore W4366339435C71924100 @default.
- W4366339435 hasIssue "19" @default.
- W4366339435 hasLocation W43663394351 @default.
- W4366339435 hasLocation W43663394352 @default.